Welcome to the Definitive Platform for Advancing TIL Therapy Drug Development
With TIL therapies rapidly expanding beyond melanoma and a new generation of engineered, persistent, and precisely characterized TILs reaching patients worldwide, the 8th TIL Therapies Summit is your golden opportunity to reconnect with peers, gain exclusive insights you won’t find anywhere else, and discover how leading organizations are evolving in this dynamic field.
Whether you're preparing for your first clinical trial, seeking innovative strategies to optimize TIL manufacturing, benchmarking your gene editing, or navigating the real-world operational challenges of rolling out these therapies at scale, this summit is the one-stop shop for everything TIL.
Unmissable Sessions
Strengthening Solid Tumor Efficacy by Engineering TILs with Precision Genome Editing to Improve Recognition & Durability
Karrie Wong, Vice President – Research, KSQ Therapeutics
See how targeted genetic edits and multiplex engineering are being used to boost tumor-specific antigen recognition, reduce exhaustion, and drive more durable responses in solid tumors.
Engineering TIL to Address the Obstacles to Wider Patient Eligibility
Giridharan Ramsingh, Vice President, Clinical Science, Obsidian Therapeutics
Discover how membrane-bound IL15 and regulatable cytokine delivery are helping expand eligibility — enabling core needle biopsy sourcing, low-dose lymphodepletion, and reduced IL2-related toxicity.
Advancing TIL Therapy in Advanced Melanoma with Clinical Evidence Supporting a Next Generation Treatment Approach
Mengmeng Tang, Vice President, Junecell
Pivotal clinical data supporting the potential first marketed TIL therapy in China, featuring an IL-2-free regimen, low-intensity pretreatment, and feeder-free manufacturing.
Q&A and Roundtable: Evaluating TIL Programs Through an Investor Lens to Drive Sustainable Growth
Samuel Svensson, CEO, NEOGAP Therapeutics & Jonas Båtelson, CEO & Co-Founder, Curacell
Two leading CEOs go head-to-head on the tough questions: balancing clinical efficacy with capital efficiency, prioritizing indications, and rebuilding investor confidence in a constrained funding environment.
Explore the Full Event Guide
- 50% C-suite Speaker Faculty
- 65% Director and above attendees
- 20+ Expert speakers
- 7+ Hours of networking
- The only place for the TILs community
Attending Companies Include
Explore the Agenda
Hear the latest breakthroughs for KSQ, Obsidian, AgonOx, in TIL therapy and gain exclusive scientific insights during our packed agenda, interactive roundtables, and expert-led panel discussions.
Partner With Us
Position your brand alongside leading solution providers, the 8th TIL Therapies Summit is where you can position your company as the name in TIL therapy.
Join TIL Therapy Experts
Be part of the most important conversations in cell therapy, connecting with attendees spanning every stage of TIL development.